• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, June 25, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study examines private insurance claims for naloxone prescriptions

Bioengineer by Bioengineer
May 3, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: A study based on a national database of private insurance claims suggests few patients at high risk of opioid overdose receive prescriptions for naloxone, which can reverse an overdose, during encounters with the health care system from hospitalizations and emergency department visits to physician visits. Among 138,108 high-risk patients, only 2,135 (1.5 percent) were prescribed naloxone. A greater likelihood of receiving naloxone was associated with prior diagnoses of opioid misuse or dependence and overdose compared to those diagnoses without overdose. A prior diagnosis of opioid overdose alone was associated with decreased likelihood of receiving naloxone compared with a prior diagnosis of opioid misuse or dependence without overdose. Study authors acknowledge their results underestimate the distribution and use of naloxone because many patients get it through programs where insurance isn’t billed or patients may pay out of pocket. The study findings also may not be generalized to patients covered by Medicaid, some Medicare plans or those who are uninsured. Still, understanding barriers, such as a lack of awareness of local laws, to physician prescribing of naloxone to high-risk patients is important so that health care encounters aren’t missed opportunities to provide the medication.

Authors: Mai T. Pho, M.D., M.P.H., of the University of Chicago Medicine, and coauthors

(doi: 10.1001/jamanetworkopen.2019.3209)

Editor’s Note: The article contains funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Embed this link to provide your readers free access to the full-text article: This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2019.3209?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050319

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. Every Friday, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Media Contact
Ashley Heher

[email protected]

Tags: DrugsHealth Care Systems/ServicesInsuranceMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

Neural Design Enables Zero-Shot Drug-Binding Proteins

June 25, 2026

Genomic Insights into Human Skin Fungi Diversity

June 25, 2026

Chiral Laser Gyroscopes Surpass Lock-In Limit

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.